Spontaneous platelet aggregation is a trigger for additional development of larger thrombi. Micro-aggregation is observed in 10% of diabetes approximately and blocked by P2Y12 inhibitors, whereas macro-aggregation is associated with overexpression of platelet α2-adrenoreceptors and is not blocked by conventional anti-platelet medicines. We examined the incidence of spontaneous platelet macro-aggregation (SPMA) in acute ischemic stroke and analyzed its clinical characteristics. Out of 665 consecutive acute ischemic strokes, SPMA was found in 10 patients (1.5%, one tenth of micro-aggregation) despite no detection in 588 control subjects. Types of ischemic stroke were 4 atherothrombotic, 4 cardioembolic, and 2 lacunar strokes. Stroke with SPMA exhibited higher (worse) values of modified Rankin Scales (mRS) at discharge (3.00 ± 0.53 vs 1.93 ± 0.07, p = 0.042 by Wilcoxon) compared with stroke without SPMA despite no difference at admission. The proportion of patients who were functionally independent (score 0–2 on the mRS) at discharge was lower in stroke with SPMA compared with stroke without SPMA (p < 0.05 by chi-square test; OR 3.60, 95% CI 1.08–12.03; RR 2.04, 95% CI 1.05–2.86). It was intriguing that severe (high magnitude) SPMA was observed in 4 atherothrombotic stroke. Although anti-platelet therapy underwent, the proportion of atherothrombotic patients who were functionally improved and independent at discharge was lower in the presence of SPMA compared with the absence of SPMA (p < 0.05 by chi-square test). The patients with SPMA were more likely to be older, having major disabilities, being less functionally improved during hospitalization, and being less functionally independent at discharge.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Rothwell PM, Algra A, Chen Z, Diener H-C, Norrving B, Mehta Z (2016) Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388:365–375
Cattaneo M (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117:2102–2112
Adamski P, Kozinski M, Ostrowska M, Fabiszak T, Navarese EP, Paciorek P et al (2014) Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost 112:224–242
Savi P, Herbert JM (2005) Clopidogrel and ticlopidine: p2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31:174–183
Hong KS, Lee SH, Kim EG, Cho KH, Chang DI, Rha JH et al (2016) Recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone. Stroke 47:2323–2330
Liu L, Wong KS, Leng X, Pu Y, Wang Y, Jing J et al (2015) Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology 85:1154–1162
Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P et al (2017) Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, doubleblind, controlled trial. Lancet Neurol 16:301–310
Matsuno H, Tokuda H, Ishisaki A, Zhou Y, Kitajima Y, Kozawa O (2005) P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 90:920–927
Araki S, Matsuno H, Haneda M, Koya D, Kanno Y, Itho J et al (2009) Correlation between albuminuria and spontaneous platelet microaggregate formation in type 2 diabetic patients. Diabetes Care 32:2062–2067
Sukekawa T, Osanai T, Nishizaki F, Metoki N, Hagii J, Kamada T et al (2013) Coupling factor 6 enhances the spontaneous microaggregation of platelets by decreasing cytosolic cAMP irrespective of antiplatelet therapy. Hypertens Res 36:520–527
Kudoh R, Mikami K, Kitajima M, Aizu K, Kitajima Y, Hagii J et al (2018) Spontaneous Micro-Aggregation of Platelets Predicts Clinical Outcome in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis 27:2074–2081
Lahiri P, Chaudhuri U, Dasgupta AK, Ray SN, Saha S, Mukherjee P (2005) Insensitivity to the alpha2-adrenergic receptor blocker yohimbine hydrochloride and occurrence of spontaneous platelet macroaggregation (SPMA) in diabetes. Platelets 16:111–115
Béres BJ, Tóth-Zsámboki E, Vargová K, László A, Masszi T, Kerecsen G et al (2008) Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost 100:829–838
Judge HM, Buckland RJ, Holgate CE, Storey RF (2005) Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets 16:398–407
Marketou ME, Kintsurashvili E, Androulakis NE, Kontaraki J, Alexandrakis MG, Gavras I et al (2013) Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanism. Int J Cardiol 168:2561–2566
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Osanai, T., Mikami, K., Kitajima, M. et al. Incidence and characteristics of spontaneous platelet macro-aggregation in acute ischemic stroke. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02185-6
- Spontaneous platelet macro-aggregation
- Ischemic stroke
- Modified Ranking Scale